SureTrader SPDR Advertisement SPDR Advertisement
Home > Boards > US Listed > Medical - Drugs >

Transgenomic Inc. (TBIO)

Add TBIO Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator
Search This Board:
Last Post: 8/3/2015 8:57:34 PM - Followers: 29 - Board type: Free - Posts Today: 0


Link to coporate website:

Share Structure
Market Value1 $40,142,705 a/o May 10, 2013
Shares Outstanding 88,225,725 a/o Mar 13, 2013
Float Not Available
Authorized Shares 100,000,000 a/o Aug 02, 2011
Par Value 0.01

Wells Fargo Bank Minnesota, N.A.
Shareowner Services
P.O. Box 64854
St. Paul, MN 55164-0854
Phone: 877-602-7611

Transgenomic is a global biotechnology company that provides unique products and services for automated high sensitivity genetic variation and mutation analysis. Our offerings include systems, products, discovery and laboratory testing services to the academic and medical research, clinical laboratory and pharmaceutical markets in the fields of pharmacogenomics and personalized medicine.

Transgenomic offers its WAVE® DHPLC Systems and associated consumables. These systems are specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification and have broad applicability to genetic research. To date there have been over 1600 systems shipped to more than 30 countries.

Transgenomic's SURVEYOR® Mutation Detection Kits and the SURVEYOR Check-It Kit provide reagents and protocols for the detection of mutations in DNA.

Transgenomic's Cytogenetics offering includes HANABI automated chromosome harvesting systems that improve laboratory productivity with consistent quality compared to manual methods.

Transgenomic Clinical Reference Laboratory provides reference laboratory services specializing in molecular diagnostics including Mitochondrial Disorders, Oncology and Hematology, Molecular Pathology and Inherited Diseases.

Transgenomic Genomic Research Services is a CRO for pharmacogenomic, translational research and clinical trials.

Colorectal Cancer Testing

Very important AMGEN signs collaberation deal with Mgmt:

"Another potential meaningful near-term contributor to the Lab Services segment (as well as to the Diagnostic Tools segment) relates to the recently consummated agreement with Amgen (NasdaqGS:AMGN) whereby the two companies are collaborating on a KRAS an NRAS gene mutation assay kit to screen patients for colorectal cancer.  The RAScan test is currently available for research use only (RUO) in the U.S. (which will run through Lab Svcs) and for clinical use in Europe - which could help accelerate instrument placements (through Menarini) as well as increase consumables sales"

CRC RAScan™ is a new mutation detection test designed to screen for selected KRAS and NRAS mutations (collectively referred to as “RAS mutations”), in patients with metastatic colorectal cancer (mCRC).The identification of these RAS mutations can give physicians important clinical information to help them make better treatment decisions for their mCRC patients.

KRAS and NRAS are part of the RAS family of genes which encode proteins involved in transmitting signals within cells. When Ras proteins are “switched on” by incoming signals, other genes involved in cell growth, differentiation, and survival are activated. Mutations in KRAS, NRAS and other related genes can lead to Ras proteins becoming permanently activated, causing overactive signaling even in the absence of incoming signals, and can lead to the uncontrolled cell growth that characterizes cancer. Mutations that permanently activate Ras proteins are found in ~25% of human tumors and up to 90% of certain cancers. About 40% of colorectal tumors carry KRAS gene mutations and these mutations have been associated with poor response to EGFR antagonists such as cetuximab and panitumumab. Therefore KRAS mutation status can be used to determine whether or not a patient with colorectal cancer will respond to anti-EGFR therapy.

The CRC RAScan test can identify mCRC patients who have RAS mutations at levels that cannot be detected using traditional Sanger Sequencing methods.

CRC RAScan™ for Colorectal Cancer Tumor Testing is available immediately from Transgenomic’s CLIA-certified laboratory in the United States. For more information on this test, click here.

CRC RAScan Mutation Detection Kits will soon be available in the U.S for research use only. CRC RAScan Mutation Detection Kits include the following kits based on Transgenomic's proprietary SURVEYOR® Nuclease technology:

  • KRAS Exon 2
  • KRAS Exons 3 & 4
  • NRAS Exons 2, 3 & 4

Zacks analyst ~ OUR 2013 OUTLOOK~

We've again made some updates to our model.  We now model 2013 revenue of $32.4 million, implying growth of 3% from 2012.  We look for Laboratory Services and Instruments to generate revenue of $20.0 million (+4%) and $12.4 million (+2%), respectively.  We think net income and EPS come in at ($12.7) million and ($0.14).


New Analyses Identify Predictive Biomarkers For Vectibix® (Panitumumab) In Patients With Metastatic Colorectal Cancer

Biomarker Analysis From Phase 3 PRIME ('203) Study and Phase 2 PEAK ('509) Study Link Additional RAS Gene Mutations to Vectibix Clinical Response

THOUSAND OAKS, Calif., May 15, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from three analyses of Vectibix® (panitumumab) in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, as a first-line treatment for metastatic colorectal cancer (mCRC). These analyses include the description of new predictive biomarkers of clinical response to Vectibix, activating mutations in KRAS (beyond exon 2) and mutations in NRAS, collectively referred to as RAS.

"Amgen helped establish KRAS gene mutation as a biomarker for lack of response to anti-EGFR treatment," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "The identification of new biomarkers may further help to identify appropriate patients with this incurable disease for such treatment."


Contact Information:
Phone: (402) 452-5437

SEC Filings:

Press Releases:

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
#481   Agreed. I think the FDA will approve alphaInvestor2 08/03/15 08:57:34 PM
#480   I agree, just draining watching this slow slide.... Tstorm 08/03/15 04:34:02 PM
#479   Very ugly. Hoping TBIO lets us know alphaInvestor2 08/03/15 03:51:08 PM
#478   Getting ugly here today...... Tstorm 08/03/15 01:55:55 PM
#477   Thats why I'm hoping for news soon! alphaInvestor2 08/03/15 10:26:22 AM
#476   The bleeding never ends here..... The only days Tstorm 08/03/15 10:07:51 AM
#475   That actually makes sense. I don't know alphaInvestor2 08/02/15 02:51:45 PM
#474   I see chemo companies benefiting from the use Golden_Gate 08/02/15 02:24:39 PM
#473   I agree. I just know that chemo companies alphaInvestor2 08/02/15 02:09:01 PM
#472   Tissue biopsies will soon be considered medieval. Golden_Gate 08/02/15 02:03:13 PM
#471   Yeah, I guess the FDA has to make alphaInvestor2 08/02/15 11:03:10 AM
#470   Im hoping that comes soon.. The thing i Tstorm 08/01/15 12:42:49 PM
#469   I would assume FDA clearance would fix the chart.... laser777 07/31/15 09:56:46 PM
#468   Chart getting ugly now........Par/Sar flip Tstorm 07/31/15 04:00:09 PM
#467   Let's hope sooner > later TBIO$$ alphaInvestor2 07/30/15 05:38:01 PM
#466   Transgenomic has booth space at the Next Generation laser777 07/30/15 05:03:00 PM
#465   The clearance is in the hands of the laser777 07/30/15 04:45:11 PM
#464   Do you have any insight or idea when alphaInvestor2 07/30/15 01:46:58 PM
#463   I hope its tomorrow AM! Go TBIO!!!! Tstorm 07/28/15 09:22:57 PM
#462   Someone is buying. Looks like FDA approval alphaInvestor2 07/28/15 10:35:16 AM
#461   Where is all the selling coming from? laser777 07/25/15 08:31:20 AM
#460   Chart is looking strong again. Hoping for alphaInvestor2 07/25/15 12:45:36 AM
#459   Huge volume into the close! Looks like we Tstorm 07/24/15 04:30:18 PM
#458   What a disaster today was, destroyed the whole chart...... Tstorm 07/23/15 09:24:44 PM
#457   Does todays selloff have something to do with Tstorm 07/23/15 03:25:29 PM
#456   always good to buy back in low but alphaInvestor2 07/23/15 02:21:14 PM
#455   Lucky I sold on early today, adding them DailyX 07/23/15 01:43:50 PM
#454   Oh well, selling off again....... UNREAL!!! Tstorm 07/23/15 01:31:39 PM
#453   TBIO looking solid this AM! Tstorm 07/23/15 10:21:41 AM
#452   That's the facade. It will act like alphaInvestor2 07/21/15 05:54:11 PM
#451   The stock doesn't act like it. Other than Tstorm 07/21/15 10:16:43 AM
#450   TBIO's holy grail is the liquid biopsy. laser777 07/21/15 09:31:34 AM
#449   Thanks, I hope to say the same about TBIO Golden_Gate 07/21/15 02:31:18 AM
#448   Up again after hours. Looks like a alphaInvestor2 07/20/15 04:49:17 PM
#447   Your guess is as good as mine alphaInvestor2 07/20/15 03:56:42 PM
#446   The selling never stops... Where is all this Tstorm 07/20/15 03:15:40 PM
#445   Time to load$$$$ TBIO$ alphaInvestor2 07/20/15 02:35:28 PM
#444   Nice work. Right at the new support alphaInvestor2 07/20/15 01:25:43 PM
#443   Picked up 2500. @ 1.61. DailyX 07/20/15 01:00:48 PM
#442   Hard to watch the bleeding every morning...... Tstorm 07/20/15 11:02:05 AM
#441   Please list pros and cons: Do you think mstachow 07/18/15 07:20:27 PM
#440   Would be perfect timing. TBIO$ alphaInvestor2 07/17/15 05:31:19 PM
#439   Uhhhhh Ohhhhhh Heavy short covering into the close.... Tstorm 07/17/15 04:29:11 PM
#438   I meant to buy another couple thousand shares alphaInvestor2 07/17/15 04:18:02 PM
#437   Pretty much normal day for any stock with alphaInvestor2 07/17/15 11:24:56 AM
#436   Yeah I really don't have an answer alphaInvestor2 07/17/15 11:10:20 AM
#435   Thats what i was thinking... Couldn`t figure out Tstorm 07/17/15 10:46:46 AM
#434   Today's filing looks positive to me. alphaInvestor2 07/17/15 10:39:40 AM
#433   New filing out? Tstorm 07/17/15 10:01:01 AM
#432   Amazing, never any bid support here... Tstorm 07/17/15 10:00:37 AM